Cost-effectiveness and budget impact of pembrolizumab+axitinib versus sunitinib in patients with advanced clear-cell renal cell carcinoma in the Netherlands.

Xander, Nicolas S H; Fiets, W Edward; Uyl-de Groot, Carin A

Xander, Nicolas S H; Fiets, W Edward; Uyl-de Groot, Carin A.

Afiliación

Xander NSH; Department of Health Technology Assessment, Erasmus School of Health Policy & Management, Erasmus University Rotterdam, Rotterdam, Netherlands.
Fiets WE; Erasmus Centre for Health Economics Rotterdam, Erasmus University Rotterdam, Rotterdam, Netherlands.
Uyl-de Groot CA; Department of Medical Oncology, Medical Center Leeuwarden, Leeuwarden, Netherlands.

Front Oncol ; 13: 1205700, 2023.

Article en En | MEDLINE | ID: mdl-37448519

Palabras clave

axitinib; budget impact; cost-effectiveness; pembrolizumab; renal cell carcinoma; societal perspective; sunitinib

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Health_economic_evaluation Aspecto: Patient_preference Idioma: En Revista: Front Oncol Año: 2023 Tipo del documento: Article País de afiliación: Países Bajos Pais de publicación: Suiza

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google